Stonepine Capital Management LLC Takes $1.71 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Stonepine Capital Management LLC bought a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 300,000 shares of the biotechnology company's stock, valued at approximately $1,713,000. Aurinia Pharmaceuticals makes up 1.6% of Stonepine Capital Management LLC's portfolio, making the stock its 13th biggest holding. Stonepine Capital Management LLC owned about 0.21% of Aurinia Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in AUPH. Eagle Asset Management Inc. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth about $92,000. Armistice Capital LLC grew its position in shares of Aurinia Pharmaceuticals by 57.7% in the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company's stock valued at $85,729,000 after purchasing an additional 3,488,000 shares in the last quarter. Privium Fund Management UK Ltd purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $593,000. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $30,000. Finally, Cantor Fitzgerald L. P. lifted its position in Aurinia Pharmaceuticals by 44.7% during the fourth quarter. Cantor Fitzgerald L. P. now owns 145,310 shares of the biotechnology company's stock worth $1,306,000 after buying an additional 44,855 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

Insider Transactions at Aurinia Pharmaceuticals

In related news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the sale, the insider now owns 456,338 shares in the company, valued at approximately $2,423,154.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

AUPH has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Aurinia Pharmaceuticals Trading Down 1.0 %

Aurinia Pharmaceuticals stock traded down $0.07 during mid-day trading on Tuesday, hitting $7.26. The company's stock had a trading volume of 871,187 shares, compared to its average volume of 1,693,178. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.05. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.04 billion, a PE ratio of -17.05 and a beta of 1.44. The stock's fifty day moving average is $6.39 and its two-hundred day moving average is $5.68.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. The firm had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. Aurinia Pharmaceuticals's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.08) EPS. On average, analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.